WO2001051924A3 - Method for determining the response to cancer therapy - Google Patents

Method for determining the response to cancer therapy Download PDF

Info

Publication number
WO2001051924A3
WO2001051924A3 PCT/US2001/001113 US0101113W WO0151924A3 WO 2001051924 A3 WO2001051924 A3 WO 2001051924A3 US 0101113 W US0101113 W US 0101113W WO 0151924 A3 WO0151924 A3 WO 0151924A3
Authority
WO
WIPO (PCT)
Prior art keywords
response
determining
cancer therapy
individual
relates
Prior art date
Application number
PCT/US2001/001113
Other languages
French (fr)
Other versions
WO2001051924A2 (en
Inventor
Sarah S Bacus
Original Assignee
Ventana Med Syst Inc
Sarah S Bacus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc, Sarah S Bacus filed Critical Ventana Med Syst Inc
Priority to CA002397772A priority Critical patent/CA2397772C/en
Priority to DE60104392T priority patent/DE60104392T2/en
Priority to AU27887/01A priority patent/AU785347B2/en
Priority to JP2001552086A priority patent/JP3699399B2/en
Priority to EP01902043A priority patent/EP1247097B1/en
Priority to AT01902043T priority patent/ATE271691T1/en
Priority to MXPA02006778A priority patent/MXPA02006778A/en
Publication of WO2001051924A2 publication Critical patent/WO2001051924A2/en
Publication of WO2001051924A3 publication Critical patent/WO2001051924A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags

Abstract

The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.
PCT/US2001/001113 2000-01-12 2001-01-12 Method for determining the response to cancer therapy WO2001051924A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002397772A CA2397772C (en) 2000-01-12 2001-01-12 Method for determining the response to cancer therapy
DE60104392T DE60104392T2 (en) 2000-01-12 2001-01-12 METHOD FOR DETECTING THE EFFECTIVENESS OF A CANCER THERAPY
AU27887/01A AU785347B2 (en) 2000-01-12 2001-01-12 Method for determining the response to cancer therapy
JP2001552086A JP3699399B2 (en) 2000-01-12 2001-01-12 Methods for determining response to cancer treatment
EP01902043A EP1247097B1 (en) 2000-01-12 2001-01-12 Method for determining the efficacy of cancer therapy
AT01902043T ATE271691T1 (en) 2000-01-12 2001-01-12 METHOD FOR DETECTING THE EFFECTIVENESS OF CANCER THERAPY
MXPA02006778A MXPA02006778A (en) 2000-01-12 2001-01-12 Method for determining the response to cancer therapy.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17651500P 2000-01-12 2000-01-12
US17651400P 2000-01-12 2000-01-12
US60/176,515 2000-01-12
US60/176,514 2000-01-12

Publications (2)

Publication Number Publication Date
WO2001051924A2 WO2001051924A2 (en) 2001-07-19
WO2001051924A3 true WO2001051924A3 (en) 2002-01-10

Family

ID=26872320

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/001438 WO2001051928A1 (en) 2000-01-12 2001-01-12 Method for quantitating a protein by image analysis
PCT/US2001/001113 WO2001051924A2 (en) 2000-01-12 2001-01-12 Method for determining the response to cancer therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001438 WO2001051928A1 (en) 2000-01-12 2001-01-12 Method for quantitating a protein by image analysis

Country Status (10)

Country Link
US (2) US7833698B2 (en)
EP (2) EP1247097B1 (en)
JP (2) JP3699399B2 (en)
AT (1) ATE271691T1 (en)
AU (2) AU2951801A (en)
CA (2) CA2397417A1 (en)
DE (1) DE60104392T2 (en)
DK (1) DK1247097T3 (en)
MX (2) MXPA02006843A (en)
WO (2) WO2001051928A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252542B2 (en) 2009-03-04 2012-08-28 Roche Diagnostics Operations Inc. Serpin B 13 as a marker for squamous cell carcinoma of the lung

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1301794B1 (en) * 2000-04-14 2009-04-01 Ventana Medical Systems, Inc. Method for quantification of akt protein expression
US20040085443A1 (en) * 2000-12-13 2004-05-06 Kallioniemi Olli P Method and system for processing regions of interest for objects comprising biological material
EP2277991A1 (en) 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
US20030165263A1 (en) * 2002-02-19 2003-09-04 Hamer Michael J. Histological assessment
GB0218909D0 (en) * 2002-08-15 2002-09-25 Qinetiq Ltd Histological assessment
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
GB0229734D0 (en) * 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
ATE366108T1 (en) * 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp DIARYL UREAS FOR PDGFR-MEDIATED DISEASES
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (en) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Methods for predicting the clinical outcome for epidermal growth factor receptor inhibitors for cancer patients
BRPI0608039A2 (en) * 2005-03-11 2009-06-16 Univ Colorado cancer cells sensitive to histone deacetylase inhibitors
WO2007086915A2 (en) 2005-05-12 2007-08-02 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
US20070091109A1 (en) 2005-09-13 2007-04-26 Roscoe Atkinson Image quality
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
DK2084268T3 (en) 2006-10-23 2019-01-21 Celularity Inc METHODS AND COMPOSITIONS FOR TREATING BONE JOIN DEFECTS WITH PLACENTACLE POPULATIONS
EP2078197B1 (en) 2006-11-01 2016-03-23 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US9697582B2 (en) 2006-11-16 2017-07-04 Visiopharm A/S Methods for obtaining and analyzing images
EP2129775A1 (en) 2007-02-12 2009-12-09 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
WO2008108059A1 (en) * 2007-03-01 2008-09-12 Nec Corporation Breast cancer pathologic image diagnosis supporting system, breast cancer pathologic image diagnosis supporting method, beast cancer pathologic image diagnosis supporting program, and recording medium in which brest cancer pathologic image diagnosis supporting program is recorded
EP3561513A1 (en) * 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101778627B (en) * 2007-07-25 2016-04-13 卫材R&D管理株式会社 Be used for the treatment of the multi-kinase inhibitor of cancer
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
JP5564431B2 (en) * 2007-10-29 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the ability of zearalenone analog compounds to treat cancer
ES2557594T3 (en) 2008-06-05 2016-01-27 Ventana Medical Systems, Inc. Method for histochemical processing and the use of a composition for histochemical processing
US8731845B2 (en) 2008-08-15 2014-05-20 Visionpharm A/S Method and a system for determining a target in a biological sample by image analysis
KR20110050688A (en) 2008-08-22 2011-05-16 안트로제네시스 코포레이션 Methods and compositions for treatment of bone defects with placental cell populations
GB2464747B (en) * 2008-10-10 2013-05-15 Hai Kang Life Corp Ltd Method for detection of analyte in microarray of samples and apparatus for performing such method
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US20100332417A1 (en) * 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
CA2767014C (en) 2009-07-02 2022-01-25 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
JP5490568B2 (en) * 2010-02-26 2014-05-14 オリンパス株式会社 Microscope system, specimen observation method and program
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9092850B2 (en) * 2011-01-21 2015-07-28 Carnegie Mellon University Identifying location biomarkers
PL2714059T3 (en) 2011-06-01 2019-04-30 Celularity Inc Treatment of pain using placental stem cells
US20130338014A1 (en) * 2012-04-05 2013-12-19 Vala Sciences, Inc. Calibration Standards For Digital Histocytometry
CA2877315A1 (en) * 2012-06-20 2013-12-27 Merrimack Pharmaceuticals, Inc. Marker quantitation in single cells in tissue sections
AU2015300915B2 (en) 2014-08-08 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
US10304188B1 (en) 2015-03-27 2019-05-28 Caleb J. Kumar Apparatus and method for automated cell analysis
CN108137701A (en) 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) For treating cancer for the near infrared light immunotherapy (NIR-PIT) for inhibiting cell
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
JP7085995B2 (en) 2015-08-18 2022-06-17 ラクテン・メディカル，インコーポレイテッド Compositions, Combinations and Related Methods for Photoimmunotherapy
US10846852B2 (en) * 2016-12-23 2020-11-24 Bio-Rad Laboratories, Inc. Reduction of background signal in blot images
WO2018207361A1 (en) * 2017-05-12 2018-11-15 オリンパス株式会社 Cell image acquisition device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003741A1 (en) * 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008185A (en) 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5109429A (en) 1985-11-04 1992-04-28 Cell Analysis Systems,Inc. Apparatus and method for analyses of biological specimens
US4741043B1 (en) * 1985-11-04 1994-08-09 Cell Analysis Systems Inc Method of and apparatus for image analyses of biological specimens
US5086476A (en) 1985-11-04 1992-02-04 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5202931A (en) * 1987-10-06 1993-04-13 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear protein
US5389523A (en) * 1988-05-31 1995-02-14 The United States Of Americas, As Represented By The Secretary Of Commerce Liposome immunoanalysis by flow injection assay
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0378383A3 (en) * 1989-01-10 1991-09-11 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA Method and device for detection, validation and quantitation of multiple-drug resistance-associated antigens
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
WO1993018186A1 (en) * 1992-03-04 1993-09-16 The Regents Of The University Of California Comparative genomic hybridization (cgh)
CA2094341A1 (en) * 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5491069A (en) * 1994-02-18 1996-02-13 The Regents Of The University Of California Biomarkers of cell senescence
US6463438B1 (en) * 1994-06-03 2002-10-08 Urocor, Inc. Neural network for cell image analysis for identification of abnormal cells
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5998151A (en) 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
US6165734A (en) 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US6447997B1 (en) * 1997-07-18 2002-09-10 Research Development Foundation Gene coding for GADD153 as a clinical diagnostic and prognostic in cancer therapy
CA2305681C (en) * 1997-09-30 2013-01-08 Peviva Ab Apoptosis-related compounds and their use
EP1030934A4 (en) * 1997-11-10 2004-03-17 Univ California Biochemical methods for detecting cervical dysplasia and cancer
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6350452B1 (en) * 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
AU770729B2 (en) * 1998-10-21 2004-02-26 Steven Jay Smith Protein quantitation with cell imaging densitometry
US6372895B1 (en) * 2000-07-07 2002-04-16 3M Innovative Properties Company Fluorogenic compounds
CA2432976A1 (en) * 2000-12-21 2002-08-08 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003741A1 (en) * 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252542B2 (en) 2009-03-04 2012-08-28 Roche Diagnostics Operations Inc. Serpin B 13 as a marker for squamous cell carcinoma of the lung

Also Published As

Publication number Publication date
US20010044124A1 (en) 2001-11-22
EP1247097B1 (en) 2004-07-21
CA2397417A1 (en) 2001-07-19
JP2003519796A (en) 2003-06-24
WO2001051928A1 (en) 2001-07-19
WO2001051924A2 (en) 2001-07-19
CA2397772C (en) 2007-06-12
JP3699399B2 (en) 2005-09-28
ATE271691T1 (en) 2004-08-15
DE60104392D1 (en) 2004-08-26
MXPA02006778A (en) 2004-04-05
AU2951801A (en) 2001-07-24
AU785347B2 (en) 2007-02-01
US7833698B2 (en) 2010-11-16
MXPA02006843A (en) 2004-04-05
US6962789B2 (en) 2005-11-08
JP2003519795A (en) 2003-06-24
DE60104392T2 (en) 2005-08-11
CA2397772A1 (en) 2001-07-19
EP1247097A2 (en) 2002-10-09
DK1247097T3 (en) 2004-11-29
US20010049114A1 (en) 2001-12-06
EP1247098A1 (en) 2002-10-09
AU2788701A (en) 2001-07-24
WO2001051928A9 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2001051924A3 (en) Method for determining the response to cancer therapy
WO2002041195A8 (en) Structural stress analysis
AU2002222959A1 (en) Transaction verification
AU2001224349A1 (en) Proteomic analysis
AU2001231064A1 (en) Data analysis software
AU2987700A (en) Fingerprint analysis method
AU2002212136A1 (en) Analysis chip
AU2308900A (en) Analysis method
WO2001086482A8 (en) Financial analysis system interface
AP2003002714A0 (en) Assaying method
AU5867901A (en) Method for detecting tumors
AU2001235460A1 (en) Method for influencing the pollen development by modifying the sucrose metabolism
AU2002246676A1 (en) Methods for determining organisms
AU2002210822A1 (en) Verification system
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2002341707A1 (en) Method for providing cardless payment
AU2002210797A1 (en) Verification system
AU2001266214A1 (en) Image processing method using variance analysis
AU2002219097A1 (en) Sensor apparatus
GB0026109D0 (en) An analysis method
AUPQ723500A0 (en) An analysis method
GB0030076D0 (en) Analysis method
ZA200105789B (en) Assaying method.
AUPQ938900A0 (en) Method and apparatus for determining the area enclosed by a planar curve
AU2001251323A1 (en) Apparatus for training or analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2397772

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006778

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 552086

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 27887/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001902043

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001902043

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001902043

Country of ref document: EP